AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently Amended) A composition for cancer treatment comprising a compound represented by formula 1 or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of lung cancer, uterine cancer, breast cancer and blood cell cancer:

wherein, R^1 is propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl grouphydrogen or a substituted or unsubstituted C_1 - C_{20} alkylcarbonyl group.

2.-3. (Cancelled)

4. (Currently Amended) A composition for the enhancement of radiosensitizing effect comprising a compound represented by formula 1 or a pharmaceutically acceptable salt:

wherein, R^1 is propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl grouphydrogen or a substituted or unsubstituted C_4 - C_{20} alkylcarbonyl group.

5.-6. (Cancelled)

7. (New) A method for treating a cancer comprising administering to a human in need of treatment a therapeutically effective amount of a compound represented by formula 1 or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from a group consisting of lung cancer, uterine cancer, breast cancer and blood cell cancer:

wherein, R¹ is hydrogen or a substituted or unsubstituted C₁-C₂₀ alkylcarbonyl group.

- 8. (New) The method according to claim 7, wherein R¹ is hydrogen, ethanoyl group, propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl group.
- 9. (New) The method according to claim 7, wherein R¹ is hydrogen, butanoyl group, hexanoyl group, or octanoyl group.
- 10. (New) A method for enhancing radiosensitizing effect effect comprising administering to a human in need of treatment a therapeutically effective amount of a compound represented by formula 1 or a pharmaceutically acceptable salt:

$$H = \begin{pmatrix} R^1 \\ N \end{pmatrix}$$
 OH OH (1)

wherein, R^1 is hydrogen or a substituted or unsubstituted C_1 - C_{20} alkylcarbonyl group.

- 11. (New) The method according to claim 10, wherein R¹ is hydrogen, ethanoyl group, propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl group.
- 12. (New) The method according to claim 10, wherein R¹ is hydrogen, butanoyl group, hexanoyl group, or octanoyl group.